Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease

Li Fan, Hocine Tighiouart, Andrew S Levey, Gerald J Beck, Mark J Sarnak, Li Fan, Hocine Tighiouart, Andrew S Levey, Gerald J Beck, Mark J Sarnak

Abstract

Current guidelines recommend under 2 g/day sodium intake in chronic kidney disease, but there are a few studies relating sodium intake to long-term outcomes. Here we evaluated the association of mean baseline 24-h urinary sodium excretion with kidney failure and a composite outcome of kidney failure or all-cause mortality using Cox regression in 840 participants enrolled in the Modification of Diet in Renal Disease Study. Mean 24-h urinary sodium excretion was 3.46 g/day. Kidney failure developed in 617 participants, and the composite outcome was reached in 723. In the primary analyses, there was no association between 24-h urine sodium and kidney failure (HR 0.99 (95% CI 0.91-1.08)) nor on the composite outcome (HR 1.01 (95% CI 0.93-1.09)), each per 1 g/day higher urine sodium. In exploratory analyses, there was a significant interaction of baseline proteinuria and sodium excretion with kidney failure. Using a two-slope model, when urine sodium was under 3 g/day, higher urine sodium was associated with increased risk of kidney failure in those with baseline proteinuria under 1 g/day and with lower risk of kidney failure in those with baseline proteinuria of ⩾ 1 g/day. There was no association between urine sodium and kidney failure when urine sodium was ⩾ 3 g/day. Results were consistent using first baseline and time-dependent urinary sodium excretion. Thus, we noted no association of urine sodium with kidney failure. Results of the exploratory analyses need to be verified in additional studies and the mechanism explored.

Figures

Figure 1. Unadjusted and adjusted restricted cubic…
Figure 1. Unadjusted and adjusted restricted cubic splines for mean baseline 24-h urinary sodium excretion and kidney failure in the entire cohort
Splines were plotted using 4 default knots. p-value for nonlinearity of urine sodium were 0.251 in unadjusted model and 0.191 in adjusted model. Dashed lines indicate 95% CIs, and rugs at the bottom show location of each value for 24-h urine sodium. Splines were adjusted for age, sex, race, cause of kidney disease, measure GFR, log urine protein, BMI, SBP, LDL cholesterol, HDL cholesterol, smoking, diabetes, history of CVD, ACE inhibitor use, diuretic use, MDRD study A or B, and randomization to blood pressure and dietary protein target.
Figure 2. Forest plot of mean baseline…
Figure 2. Forest plot of mean baseline 24-h urinary sodium excretion and kidney failure in the entire cohort and subgroups
Hazard ratios (HRs) (95% CI) were per 1 g/d higher urine sodium, and HRs were log scale. p-int was p-value for the interaction. The hazard ratios were adjusted for age, sex, race, cause of kidney disease, measure GFR, log urine protein, BMI, SBP, LDL cholesterol, HDL cholesterol, smoking, diabetes, history of CVD, ACE inhibitor use, diuretic use, MDRD study A or B, and randomization to blood pressure and dietary protein target.
Figure 3. Unadjusted and adjusted restricted cubic…
Figure 3. Unadjusted and adjusted restricted cubic splines for mean baseline 24-h urinary sodium excretion and kidney failure stratified by baseline proteinuria
Splines were plotted using 4 default knots. p-value for nonlinearity of urine sodium were 0.005 in unadjusted model and 0.003 in adjusted model. Thin dashed lines indicate 95% CIs, and rugs at the bottom and top showed location of each value for 24-h urine sodium in those with baseline urine protein < 1g/d and ≥ 1 g/d, respectively. Splines were adjusted for age, sex, race, cause of kidney disease, measure GFR, log urine protein, BMI, SBP, LDL cholesterol, HDL cholesterol, smoking, diabetes, history of CVD, ACE inhibitor use, diuretic use, MDRD study A or B, and randomization to blood pressure and dietary protein target, and interaction between urine sodium and baseline urine protein.

References

    1. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.
    1. Forman JP, Scheven L, de Jong PE, et al. Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension. Circulation. 2012;125:3108–3116.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements. 2012;2:337–414.
    1. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2011;378:380–382.
    1. O’Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229–2238.
    1. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305:1777–1785.
    1. Ekinci EI, Clarke S, Thomas MC, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34:703–709.
    1. Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861–866.
    1. Swift PA, Markandu ND, Sagnella GA, et al. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension. 2005;46:308–312.
    1. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19:999–1007.
    1. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.
    1. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82:330–337.
    1. Vegter S, Perna A, Postma MJ, et al. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol. 2012;23:165–173.
    1. He FJ, Marciniak M, Visagie E, et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension. 2009;54:482–488.
    1. World Health Organization. [October 5–7, 2006];WHO forum on reducing salt intake in populations. .
    1. Kotchen TA, Cowley AW, Jr, Frohlich ED. Salt in health and disease--a delicate balance. N Engl J Med. 2013;368:1229–1237.
    1. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649–1661.
    1. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–1673.
    1. Norris KC, Greene T, Kopple J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol. 2006;17:2928–2936.
    1. Dunkler D, Dehghan M, Teo KK, et al. Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus. JAMA Intern Med. 2013
    1. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–448.
    1. Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA. 1998;279:1383–1391.
    1. Vallon V, Thomson SC. Anomalous role for dietary salt in diabetes mellitus? Nat Rev Endocrinol. 2011;7:377–378.
    1. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877–884.
    1. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762.

Source: PubMed

3
구독하다